A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer

BACKGROUND: Pembrolizumab and sintilimab have both been approved by the China National Medical Products Administration (NMPA) for the first-line treatment of advanced non-small cell lung cancer (NSCLC). These two drugs have several differences in biological characteristics and population in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kai, Fu, Yifan, Zeng, Daxiong, Chen, Tao, Wang, Changguo, Jiang, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987820/
https://www.ncbi.nlm.nih.gov/pubmed/35399230
http://dx.doi.org/10.21037/jtd-22-225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987820/
https://www.ncbi.nlm.nih.gov/pubmed/35399230
http://dx.doi.org/10.21037/jtd-22-225

Ejemplares similares